Aurinia Closing In On Lupus Nephritis With Voclosporin

Phase III AURORA Study Reports Positive Top-Line Data

Canada’s Aurinia Pharmaceuticals expects to file a US NDA in the first half of next year on the use of its next-generation calcineurin inhibitor, voclosporin, in lupus nephritis, a condition with no approved therapies.

Kidney_Disease
• Source: Shutterstock

Just-reported top-line data from Aurinia Pharmaceuticals Inc.’s pivotal Phase III AURORA study show the drug has positive effects on clinical endpoints when used on top of background therapy with mycophenolate mofetil and low-dose corticosteroids.

The share price of Victoria, BC-based Aurinia more than doubled in after-hours trading on NASDAQ on 4 December, the day...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Genitourinary

More from Therapeutic Category